托法替布在类风湿关节炎、银屑病关节炎、溃疡性结肠炎和银屑病临床试验中的特殊关注不良事件:37 066患者年暴露分析
该分析汇总38项托法替布临床试验(类风湿关节炎、银屑病关节炎、溃疡性结肠炎、银屑病),共13 567例患者、37 066患者年暴露,评估特殊关注不良事件发生率。结果显示感染和侵染类事件最常见,带状疱疹和严重感染发生率最高,各疾病间安全性特征总体一致。
要点
- 感染和侵染类不良事件在各疾病中均最常见。
- 带状疱疹和严重感染是发生率最高的特殊关注不良事件。
- 年龄和性别调整后死亡率比在各队列中均≤0.2。
核心结论
- 托法替布安全性特征在各疾病间总体一致,且与既往分析相比长期随访结果一致。
研究设计与样本
- 汇总38项托法替布1、2、3或3b/4期临床试验及长期扩展研究,涵盖类风湿关节炎23项、银屑病关节炎3项、溃疡性结肠炎5项、银屑病7项。
- 纳入至少接受1剂托法替布的患者13 567例,总暴露37 066患者年;类风湿关节炎最大暴露时长10.5年。
主要发现
- 感染和侵染系统器官类不良事件在所有疾病中均最常见。
- 带状疱疹(非严重和严重)发生率分别为类风湿关节炎3.6、银屑病关节炎1.8、溃疡性结肠炎3.5、银屑病2.4(每100患者年)。
- 严重感染发生率分别为类风湿关节炎2.5、银屑病关节炎1.2、溃疡性结肠炎1.7、银屑病1.3(每100患者年)。
- 按国家加权的年龄和性别调整死亡率比在各队列中均≤0.2。
关键数值与推荐
- 特殊关注不良事件发生率以每100患者年唯一事件患者数表示。
- 带状疱疹发生率:类风湿关节炎3.6、银屑病关节炎1.8、溃疡性结肠炎3.5、银屑病2.4。
- 严重感染发生率:类风湿关节炎2.5、银屑病关节炎1.2、溃疡性结肠炎1.7、银屑病1.3。
- 年龄和性别调整死亡率比(按国家加权)在各队列中均≤0.2。
临床怎么用
- 临床使用托法替布时应关注感染和侵染类事件,尤其是带状疱疹和严重感染。
- 不同疾病患者使用托法替布时安全性监测原则可参照一致的总体特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To analyse adverse events (AEs) of special interest across tofacitinib clinical programmes in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC) and psoriasis (PsO), and to determine whether the incidence rates (IRs; unique patients with events per 100 patient-years) of these events are consistent across diseases. METHODS: The analysis included data from patients exposed to ≥1 dose of tofacitinib in phase 1, 2, 3 or 3b/4 clinical trials and long-term extension (LTE) studies (38 trials) in RA (23 trials), PsA (3 trials), UC (5 trials) and PsO (7 trials). All studies were completed by or before July 2019, except for one ongoing UC LTE study (data cut-off May 2019). IRs were obtained for AEs of special interest. RESULTS: 13 567 patients were included in the analysis (RA: n=7964; PsA: n=783; UC: n=1157; PsO: n=3663), representing 37 066 patient-years of exposure. Maximum duration of exposure was 10.5 years (RA). AEs within the 'infections and infestations' System Organ Class were the most common in all diseases. Among AEs of special interest, IRs were highest for herpes zoster (non-serious and serious; 3.6, 1.8, 3.5 and 2.4 for RA, PsA, UC and PsO, respectively) and serious infections (2.5, 1.2, 1.7 and 1.3 for RA, PsA, UC and PsO, respectively). Age-adjusted and sex-adjusted mortality ratios (weighted for country) were ≤0.2 across cohorts. CONCLUSIONS: The tofacitinib safety profile in this analysis was generally consistent across diseases and with longer term follow-up compared with previous analyses.
引用
- Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021. PMID: 34045358. doi:10.1136/rmdopen-2021-001595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。